13^th European Pathology Congress August 02-03, 2017 Milan, Italy

Qihui (Jim) Zhai is currently working as a Professor of Laboratory Medicine and Pathology College of Medicine, Mayo Clinic. He obtained his medical degree from Shandong Medical University, China. He is honoured as Top Pathologists by Consumer’s Research Council of America. He has published more than 100 works in peer reviewed journals. His research interest includes pathology and cancer.

Pathology

Victor Tron is currently working as a professor at university of Toronto. He has completed his medical education at University of Alberta, Edmonton in 1982. He has chaired many national & international meetings and served as member for Associations. Currently he is associated with Canadian Associations of Pathologists. He is also an editorial board member journal of Cutaneous Medicine and Surgery.

Pathology

Carol Apt received her Ph.D. in Sociology from Northeastern University in Boston, Massachusetts (USA), her M.A. in Sociology from Boston University in Boston, Massachusetts (USA), and her B.A. in Sociology from Indiana University in Indianapolis, Indiana. She also has a Certificate of French Studies from Ecole Lemania in Lausanne, Switzerland. Dr. Apt is currently a Professor of Sociology at South Carolina State University in Orangeburg, South Carolina, where she has been for the last 15 years. During that time she has taught Medical Sociology, Human Sexuality, Cultural Anthropology, Social Problems, and the Sociology of Genocide, among others. She is also a member of the South Carolina Medical Association Bioethics Committee and the Ethics Committee of The Regional Medical Center in Orangeburg, South Carolina. In addition, Dr. Apt is the host of a live, call-in radio talk show called ‘Talk to Me,’ which is broadcast on 90.3 FM-WSSB, also in Orangeburg. During her show she addresses listeners’ questions about sexuality and relationships.

Sociology

Sergey V Brodsky has completed his MD and PhD in 1992 and 1995, perspectively from North Ossetian Medical Academy in Russia. His research interests include renal pathology, renal physiology, vascular biology and angiogenesis. After finishing a residency in anatomic pathology and a fellowship in renal pathology in 2009, he currently works as a renal pathologist at the OSU. He has published more than 95 papers in peer-reviewed journals and book chapters

Renal Pathology & Renal Physiology

Dr. Luo has been studying molecular pathology related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate cancer and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7 and MCM7-SF3B3 oncogenic pathways. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these findings advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies

Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate cancer and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3, CSR1-SF3A3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, AR-MCM7 and MCM7-SF3B3 oncogenic pathways.

Born in Milan, July 4, 1944. 1962-1968: School of Medicine, University of Milan. 1965-1968: Studied in Institute of General Pathology, University of Milan. 1968: M.D., magna cum laude, discussing an experimental thesis on the radiosensitizing properties of aliphatic aldehydes. 1969 to present: Several positions on faculty of Institute of General Pathology, University of Milan. 1971-1985: Associate Professor of General Pathology, Faculty of Medicine and Surgery, University of Milan. 1973-1985: Assistant to the Chairman of General Pathology, Faculty of Medicine and Surgery, University of Milan. 1975: NATO fellowship. 1976: He worked at the Institute of Biochemistry of the University of Helsinki (Finland). 1979: Invited speaker at the round table on “Polyamines and Neoplastic Growth” at the Gordon Conference on Polyamines in Andover, NH (USA). Writer of a review on “Polyamines in Mammalian Tumors” to be published in “Advances in Cancer Research”. 1981: Selected to Corresponding Membership of the American Association for Cancer Research. The cover of the April issue of The Journal of the National Cancer Institute has been entirely addressed to the paper on the circadian rithm of hepatic ornithine decarboxylase during hepatocancinogenesis in the rat. 1982: Invited speaker at 41° Bat Sheva Seminar on “Polyamines in Growth and Differentiation Processes” in Jerusalem (Israel). 1983: Invited speaker at the 12th NATO Course on “Pineal Gland and its Endocrine Role”, held in Erice (Italy). 1986 to present: Professor of General Pathology, Faculty of Medicine and Surgery, University of Milan. 1986: Invited speaker at the International Conferences on “Polyamines in Life Sciences” in Lake Yamanaka (Japan). 1986: Invited speaker and chairman at the International Meeting on Brain Oncology” held in Rennes (France). 1987: Organized of a International Meeting on “Polyamines in Biology and Medicine”, held in Milan (Italy). 1988: Invited speaker at the International Symposium on “Polyamines in Biochemical and Clinical Research”; held in Sorrento (Italy). 1993: Invited speaker at the International Symposium “Thomas Addison and Its Diseases: 200 Years on”, held in London (U.K.). 1996: Invited chairman at the Tokyo International Symposium on Polyamines, held in the Shoan Village Center (Japan). 1998 to 2004: Director of the Institute of General Pathology, Faculty of Medicine and Surgery, University of Milan. 2000 to 2006: Scientific Coordinator of the PhD course in “Experimental Pathology and Neuropathology” of the Faculty of Medicine and Surgery of the University of Milan. 2003: Invited speaker at the 3rd International Conference on Hyperhomocysteinemia, Saarbrücken, Germany. Invited speaker at the Symposium on “B12 and Multiple Sclerosis” for ECTRIMS (Milan). 2005: Invited speaker at the Gordon Research Conference on “Vitamin B12 and Corphins”, Oxford, U.K. Invited speaker at the 5th International Conference on Homocysteine Metabolism, Milan, Italy. 2006-2012: Director of the Post-graduate School of Biomedical Clinical and Experimental Sciences at the Faculty of Medicine and Surgery of the University of Milan. 2007: Invited speaker at ”The Global College of Neuroprotection and Neuroregeneration” (4th Annual Conference), Garmisch, Germany. 2008: Elected Corresponding Member of the “Istituto Lombardo – Accademia di Scienze e Lettere” (Milan, Italy). 2011: Member of the Editorial Board of “Chinese Journal of Clinicians” (Electronic Edition). 2012: Member of the Editorial Board of “Scientifica” (Neurology Section). Invited speaker and chairman at the “Advances and Controversies in B-Vitamins and Choline 2012” conference, Leipzig, Germany. Invited speaker at the “Vitamin B12 Symposium”, Nancy, France. -2013: Member of the Editorial Board of “World Journal of Meta-Analysis". Member of the Editorial Board of “Autoimmune Disease & Therapeutic Approaches: Open Access”. Member of the Editorial Board of “Journal of Blood Disords”.

Pathology, Clinical Pathology, neurobiology, oncology, and molecular biology.

Dr. Liang Cheng is Virgil H. Moon Endowed Professor of Pathology and Urology at Indiana University School of Medicine, Indianapolis, Indiana, USA. Currently, he is Chief of the Genitourinary Pathology Service, Director of the Urologic Pathology Fellowship, and Director of Molecular Diagnostics and Molecular Pathology Laboratories. Dr. Cheng is board certified in Molecular Genetic Pathology, Anatomic and Clinical Pathology by the American Board of Pathology. Dr. Cheng has received numerous prestigious awards including the Stowell-Orbison Award from the United States and Canadian Academy of Pathology (USCAP) and the Koss Medal Award from the International Society of Urological Pathology (ISUP). Dr. Cheng received the Arthur Purdy Stout Prize from the Arthur Purdy Stout Society of Surgical Pathologists in recognition of outstanding contributions to the field of surgical pathology for a surgical pathologist less than 45 years old. Dr. Cheng has published over 780 peer-reviewed SCI articles in high-impact scientific journals. His published work has been cited more than 30,000 times (ISI Web of Science h-index: 87). He is also the author of over 80 book chapters and several books, including Bladder Pathology, Urologic Surgical Pathology, Essentials of Anatomic Pathology, Molecular Genetic Pathology, Atlas of Genitourinary Pathology, Molecular Surgical Pathology, Rare Tumors and Tumor-like Conditions, Pathology of the Urinary Bladder-An Algorithmic Approach, and Atlas of Anatomic Pathology (Series Editor). Currently, he is an active member of over 30 Editorial Boards, including Molecular Cancer (Associate Editor), Human Pathology (Senior Associate Editor), American Journal of Surgical Pathology, Modern Pathology, Histopathology, Journal of Pathology, Journal of Clinical Pathology, European Journal of Cancer, Pathology, Future Oncology, Urologic Oncology, Expert Review of Anticancer Therapy, Critical Reviews in Oncology/Hematology and others. In 2015, Dr. Cheng was ranked among the Top 10 World’s Experts in Urogenital Neoplasms, and No. 5 in the field of Bladder Cancer by Expertscape (http://www.expertscape.com/leaders/bladder-cancer). Dr. Cheng's research focuses on translational studies of genitourinary cancers and molecular diagnostics of solid tumors.

Bladder Pathology, Urologic Surgical Pathology, Essentials of Anatomic Pathology, Molecular Genetic Pathology

Graduated in Pharmacy at the Federal University of Rio de Janeiro, PhD in Sciences at the Federal University of Rio de Janeiro. He is currently professor at the Federal University of Santa Catarina and coordinates the Stem Cell and Bioengineering Laboratory. The Laboratory investigates the role of mesenchymal stem cells in the repair of neural injury as well as bone regeneration. Three-dimensional scaffolds for cultivation and maintenance of mesenchymal stem cells are one of the lines of research of the Stem Cell and Bioengineering Laboratory. The Laboratory also investigates how mesenchymal stem cells can act as support for the ex vivo expansion of hematopoietic stem cells. The Stem Cell and Bioengineering Laboratory evaluates how amplification of hematopoietic stem cell can target allogeneic hematopoietic stem cell transplantation.

1.Neuronal regeneration in stroke; 2.Stem Cells; 3.Scaffolds for bone tissue engineering; 4.Amplification ex vivo of hematopoietic stem cells; 5.Leukemia and lymphoma.

Reinhard Büttner is Professor and Chairman of The Institute of Pathology at University Hospital Cologne, Köln, Germany, and the Co-Founder and Chief Scientific Officer of TARGOS Molecular Diagnostics. He completed his medical degree at the University of Mainz, Mainz, Germany, in 1985, before starting a residency at Rheinisch-Westfalische Technische Hochschule RWTH Aachen, Aachen, Germany. In 1987, he began post-doctoral work at the Gene Centre Munich and MD Anderson Cancer Centre, Houston, TX, USA (1987‒1990). Returning to Germany in 1991, he took up a residency at the University of Regensburg, before becoming Professor and Chairman for Pathology at RWTH Aachen (1999‒2001). After which, he worked as a Professor and Chairman of Pathology at the University of Bonn (2001‒2011), before being appointed to his current position as Professor and Chairman of Pathology at the University of Cologne in 2011. Reinhard Büttner specialises in molecular pathology and is a member of a number of academic societies including the German Society of Pathology and the International Academy of Pathology. He is the Co-President of the International Academy of Pathology World Congress of Pathology, Cologne 2016. He has more than 450 peer-reviewed papers published in high-impact internationally renowned journals.

molecular pathology

•Joined as a Faculty member (as Assistant Professor) at MAMC, after completing training (DNB) in Nephrology at AIIMS New Delhi since 1990 •National team of trainers on AIDS, under NACO-WHO project in 1993 •Faculty member and Consultant Nephrologist at International Islamic University Kuantan, Malaysia – 1998-2002 •Faculty Incharge- Nephrology, Deptt Of Medicine MAMC&LNH -1997 and as a Professor since 1998- 2008 •WHO fellowship in Community Health Care Research in 2007 •Director Professor (2008-09) and currently Head of the Medicine De Dr partment since Sept 2016 •Created Deptt. Of Nephrology -2016 •Published many scientific paper in International and National journal and have been guiding post graduate students in medicine for their thesis since 1992 •He is a active member of Indian society of nephrology , association of physician of India and International society of Nephrology

Nephrology, Clinical Pathology

Dr. Holladay serves as the American Society for Clinical Pathology (ASCP) Chief Executive Officer. He has focused on globalization initiatives for the medical laboratory community that include significant contributions to the President’s Emergency Plan for AIDS Relief (PEPFAR) funded through the Centers for Disease Control and Prevention; strategic partnerships in laboratory medicine; corporate reorganization/management activities; mergers and acquisitions; international outreach; external partnerships; and health services research and delivery. ASCP has been funded for over $40 million to support patient-centered care. His scientific research work focuses in the areas of cytopathology and molecular research. He’s been funded as a Principal Investigator for 50 scientific research grants and 100 scientific corporate contracts. He has published a number of significant research articles within the profession and is the primary author of several textbooks that are international best sellers. He is an active scientific lecturer and has given over 170 national and international speeches.

Pathology, Clinical Pathology